Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"

Rhea-AI Summary

Armata Pharmaceuticals (ARMP) announced a peer-reviewed publication in Communications Biology titled "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection." The paper describes near-atomic cryo-EM structures of phage P7-1, a component of Armata's AP-PA02 phage cocktail.

The study reports dual tail-fiber architecture that locks the tail sheath to preserve stability and a conformational cascade that releases the lock on host recognition. Armata notes AP-PA02 is being developed for chronic Pseudomonas aeruginosa respiratory infections and has completed two Phase 2 trials, SWARM-P.a. and Tailwind.

Positive

• Peer-reviewed cryo-EM publication in Communications Biology
• Structural insight into P7-1 explains enhanced virion stability
• P7-1 structural blueprint supports engineering of next-generation phages

Negative

• No new clinical or financial data reported from Phase 2 trials

News Market Reaction – ARMP

+10.80%

15 alerts

+10.80% Session close to close

+16.2% Peak in 24 hr 23 min

$401.81M Market Cap

1.4x Rel. Volume

In the May 4 session, ARMP gained 10.80%, reflecting a significant positive market reaction. Argus tracked a peak move of +16.2% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +10.8% in the session following this news. A strong positive reaction aligns with A...

Analysis

The stock surged +10.8% in the session following this news. A strong positive reaction aligns with Armata’s ongoing clinical and scientific progress. Prior updates, such as QIDP designation and Phase 3 planning, produced mixed but sometimes positive responses. The structural biology paper in Communications Biology underscores mechanistic understanding of AP-PA02’s component phage P7-1, which could support confidence in product stability and design. However, investors would still need to weigh existing financing needs and shelf capacity of $100,000,000 when judging sustainability of any large move.

Key Figures

Phase 2 trials for AP-PA02: 2 trials

1 metrics

Phase 2 trials for AP-PA02 2 trials SWARM-P.a. and Tailwind Phase 2 studies reported as promising

Historical Context

5 past events · Latest: Apr 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 27	Board appointment	Positive	-14.9%	Pfizer executive Daniel B. Gilmer joins Board to add commercial expertise.
Mar 25	Earnings results	Negative	+8.6%	Large 2025 net loss, going‑concern language, higher liabilities and stockholders’ deficit.
Mar 19	Results delay & update	Neutral	-2.9%	Delay of Q4 results alongside AP-SA02 Phase 3 planning and facility progress.
Feb 23	Regulatory designation	Positive	+9.3%	FDA grants QIDP designation to AP-SA02, supporting future Phase 3 strategy.
Jan 13	Clinical pathway	Positive	-4.9%	End‑of‑Phase 2 feedback supports advancing AP-SA02 into Phase 3 superiority trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows multiple divergences, with shares sometimes declining on positive clinical or regulatory milestones and rising despite weak financial results.

Recent Company History

Over the last few months, Armata reported several key developments. An End-of-Phase 2 FDA response and subsequent QIDP designation for AP-SA02 supported plans for a Phase 3 superiority trial starting in H2 2026. Despite these encouraging clinical signals, market reactions have been mixed, with both gains and losses following positive updates. Financial filings highlighted substantial net losses, going‑concern language, and reliance on external funding. A recent board appointment added commercial expertise as Armata advances its late clinical-stage bacteriophage programs, and today’s structural biology publication fits into this ongoing development narrative.

Key Terms

bacteriophage, cryo-electron microscopy, virion, genome ejection, +4 more

8 terms

bacteriophage medical

"focused on the development of high-purity, pathogen-specific bacteriophage therapeutics"

A bacteriophage is a virus that infects and kills specific bacteria, acting like a precision tool that targets only certain bacterial strains. For investors, bacteriophage-based products matter because they represent an alternative to traditional antibiotics, potentially addressing drug-resistant infections and creating new markets in healthcare and agriculture; success or failure in development and regulation can sharply affect the value of companies working in this field.

cryo-electron microscopy technical

"near-atomic snapshots achieved in these experiments using state-of-the-art cryo-electron microscopy"

A technique that makes extremely detailed, three‑dimensional 'photographs' of biological molecules by freezing them and scanning them with an electron beam, revealing shapes too small for ordinary microscopes. For investors, it matters because knowing precise molecular structures speeds drug and vaccine discovery, helps companies design more effective therapies, and can reduce development risk and time—similar to having an exact blueprint before building a complex machine.

virion medical

"Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection"

A virion is a complete, infectious virus particle made of genetic material wrapped in a protective coat and sometimes an outer membrane. It is the unit that can move between hosts and start infection, so how many virions are present and how they behave affects how contagious a disease is, how vaccines, tests and treatments must be built, and what safety or regulatory controls companies in healthcare and biotech must follow — like a seed determining whether a plant will grow, a virion determines transmission and related business risk.

genome ejection medical

"Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection"

Genome ejection is the moment a virus or virus-like particle releases its genetic material into a host cell so the genetic instructions can take over the cell’s machinery. Think of it like a syringe delivering a blueprint into a factory; understanding when and how that delivery happens matters to investors because it is a core target for antiviral drugs, gene-delivery technologies and diagnostics that can affect the value of biotech and pharmaceutical developments.

tail fibers medical

"we found that P7-1 carries two distinct sets of tail fibers anchored to the same baseplate"

Tail fibers are thin, flexible protein appendages on certain viruses that act like grappling hooks or keys, allowing the virus to recognize and attach to specific host cells (often bacteria). Investors care because changes or engineering of tail fibers determine which cells a therapeutic or diagnostic virus can target, affecting a product’s effectiveness, safety profile, regulatory pathway and commercial potential—key drivers of a biotech company’s value.

baseplate medical

"two distinct sets of tail fibers anchored to the same baseplate"

A baseplate is a flat structural piece that serves as the foundation for mounting, aligning or connecting parts in a device, machine, medical implant or lab instrument—think of it as the building’s foundation or smartphone chassis for the product’s components. Investors should care because the design, material quality and supply of baseplates affect manufacturing costs, product reliability, regulatory approval risks and the ability to scale production, all of which influence a company’s performance and valuation.

conformational cascade medical

"a coordinated conformational cascade is triggered: the long tail fibers engage the host"

A conformational cascade is a chain of stepwise changes in the three-dimensional shape of a molecule or protein, where one structural shift triggers the next and collectively alters the molecule’s function. For investors, these cascades matter because they often determine whether a drug or diagnostic behaves as intended—affecting potency, side effects, stability and the likelihood of clinical success and regulatory approval, like a row of dominos where the first tilt sets the whole outcome.

host specificity medical

"engineering next-generation phage therapeutics with enhanced stability and precisely tuned host specificity"

Host specificity is the degree to which a biological agent (like a virus, bacterium, or engineered therapy) targets and affects particular species, tissues, or cell types rather than others. For investors, it matters because high specificity can mean safer, more effective products and narrower regulatory hurdles, while low specificity can increase safety risks, broaden market potential or regulatory complexity — like a key that fits only one lock versus many locks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02

LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in Communications Biology, a peer-reviewed journal from Nature Portfolio.

The publication, titled, "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection," describes the structure of phage P7-1, which is included in Armata's multi-phage cocktail, AP-PA02. Armata is developing AP-PA02 as a potential treatment for chronic respiratory infections due to Pseudomonas aeruginosa in people with cystic fibrosis (CF) and with non-cystic fibrosis bronchiectasis (NCFB). AP-PA02 has shown promising results in two Phase 2 clinical trials to date, SWARM-P.a. (NCT04596319) and Tailwind (NCT05616221). Armata remains focused on proving the clinical utility of phages as well as conducting bench science to deepen the knowledge of phage mechanism of action.

"Understanding the structure of our phages is an important element of our development strategy, including life cycle management of our clinical product candidates," stated Dr. Deborah Birx, Chief Executive Officer of Armata, and co-author of the paper. "This publication reflects Armata's ongoing commitment to understanding phage structure and function, enhancing our knowledge of fundamental phage biology to enable the development of novel antibacterial therapies. Importantly, the high purity of Armata's phages was essential to enabling the near-atomic snapshots achieved in these experiments using state-of-the-art cryo-electron microscopy."

Dr. Gino Cingolani, Anderson Family Endowed Chair in Medical Education, Research & Patient Care, and Professor in the Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, and senior author of the paper, stated, "This study marks our third collaboration with Armata on therapeutic bacteriophages and reports the first structural characterization of a member of the Pakpunavirus genus. Using state-of-the-art cryo-electron microscopy, we captured near-atomic snapshots of Pakpunavirus P7-1, revealing with unprecedented precision how phage architecture governs function and providing a mechanistic explanation for a key property of this therapeutic phage—its stability during storage. Unexpectedly, we found that P7-1 carries two distinct sets of tail fibers anchored to the same baseplate. In the absence of a host, these fibers fold tightly along the tail sheath, nestling into grooves formed by the sheath proteins to lock the tail in place and prevent premature contraction. Upon recognition of a bacterial host, a coordinated conformational cascade is triggered: the long tail fibers engage the host and pull the shorter fibers out of their grooves, releasing the lock and initiating infection. The structural atlas of P7-1 advances our understanding of phage infection mechanisms and provides a blueprint for engineering next-generation phage therapeutics with enhanced stability and precisely tuned host specificity."

The full paper can be found here.

About Armata Pharmaceuticals, Inc.
Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices ("cGMP") manufacturing to support full commercialization.

Forward Looking Statements
This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; Armata's planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Media Contacts:

At Armata:

Pierre Kyme
ir@armatapharma.com
310-665-2928

Investor Relations:

Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-structural-biology-publication-in-communications-biology-302760348.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

What did Armata announce about phage P7-1 in May 2026 (ARMP)?

Armata published a structural study of phage P7-1 using cryo-EM. According to Armata, the paper shows near-atomic structures revealing dual tail fibers and a stability mechanism informing phage engineering and product development.

How does the P7-1 structure affect AP-PA02 stability and use (ARMP)?

The structure reveals a locking mechanism that preserves tail stability in storage. According to Armata, two tail-fiber sets fold into sheath grooves to prevent premature contraction, then deploy upon host recognition to initiate infection.

Is AP-PA02 in clinical trials for Pseudomonas infections (ARMP)?

Yes. According to Armata, AP-PA02 has completed two Phase 2 trials, SWARM-P.a. and Tailwind. The company is developing AP-PA02 for chronic Pseudomonas aeruginosa respiratory infections in CF and NCFB patients.

What practical benefits does the P7-1 structural atlas provide for ARMP therapeutics?

It provides a blueprint for engineering stability and host specificity in therapeutic phages. According to Armata, the mechanistic details support design of next-generation phages with tuned host range and improved storage properties.

Where was the P7-1 study published and who collaborated with Armata (ARMP)?

The study was published in Communications Biology with University of Alabama at Birmingham collaborators. According to Armata, the paper lists UAB researchers as senior authors and notes this is their third collaboration on therapeutic bacteriophages.